miRNA-223在子宫肌瘤组织中的表达及临床意义分析
|
摘要
目的:探讨miRNA-223在子宫肌瘤组织中的表达及临床意义。方法:选取2018年1-6月在本院行子宫肌瘤剔除术的子宫肌瘤患者60例为子宫肌瘤组,另选同期到本院体检的30例健康女性为正常对照组。采用RT-PCR法检测两组血清、子宫肌瘤组织和瘤旁正常组织中miRNA-223的表达,并分析miRNA-223表达与子宫肌瘤患者临床病理特征的关系。结果:子宫肌瘤组miRNA-223表达水平明显高于正常对照组(P<0.05);子宫肌瘤组织miRNA-223表达水平明显高于瘤旁正常组织(P<0.05);子宫肌瘤组织中miRNA-223的表达水平与年龄、肌瘤大小、肌瘤个数、病理类型及月经情况均有关(P<0.05);由ROC曲线可知,其曲线下面积为0.847,95%CI(0.628,1.395),当miRNA-223的截断值为≥6.50时,其诊断敏感度为91.43%,特异度为80.26%。结论:miRNA-223在子宫肌瘤组织中呈高表达,其表达可能与子宫肌瘤的发生发展密切相关。
Objective:To investigate the expression and clinical significance of miRNA-223 in hysteromyoma.Method:60 patients with hysteromyoma who underwent hysteromyomectomy in our hospital from January to June 2018 were selected as hysteromyoma group,30 healthy women who came to our hospital for physical examination at the same time were selected as normal control group.RT-PCR was used to detect the expression of miRNA-223 in serum of two groups,the expression of miRNA-223 in hysteromyoma and normal tissue adjacent to tumors,the relationship between the expression of miRNA-223 and the clinicopathological characteristics of patients with hysteromyoma were analyzed.Result:The expression level of miRNA-223 in hysteromyoma group was significantly higher than that of normal control group(P<0.05).The expression level of miRNA-223 in hysteromyoma tissue was significantly higher than that of normal tissue adjacent to tumors(P<0.05).The expression level of miRNA-223 in hysteromyoma was correlated with age,size of leiomyoma,number of leiomyomas,pathological type and menstruation(P<0.05).The ROC curve showed that the area under the curve was 0.847,95%CI(0.628,1.395),when the cut-off value≥6.50,the diagnostic sensitivity and specificity were 91.43% and 80.26% respectively.Conclusion:miRNA-223 is highly expressed in uterine fibroids,and its expression may be closely related to the occurrence and development of uterine fibroids.
Objective:To investigate the expression and clinical significance of miRNA-223 in hysteromyoma.Method:60 patients with hysteromyoma who underwent hysteromyomectomy in our hospital from January to June 2018 were selected as hysteromyoma group,30 healthy women who came to our hospital for physical examination at the same time were selected as normal control group.RT-PCR was used to detect the expression of miRNA-223 in serum of two groups,the expression of miRNA-223 in hysteromyoma and normal tissue adjacent to tumors,the relationship between the expression of miRNA-223 and the clinicopathological characteristics of patients with hysteromyoma were analyzed.Result:The expression level of miRNA-223 in hysteromyoma group was significantly higher than that of normal control group(P<0.05).The expression level of miRNA-223 in hysteromyoma tissue was significantly higher than that of normal tissue adjacent to tumors(P<0.05).The expression level of miRNA-223 in hysteromyoma was correlated with age,size of leiomyoma,number of leiomyomas,pathological type and menstruation(P<0.05).The ROC curve showed that the area under the curve was 0.847,95%CI(0.628,1.395),when the cut-off value≥6.50,the diagnostic sensitivity and specificity were 91.43% and 80.26% respectively.Conclusion:miRNA-223 is highly expressed in uterine fibroids,and its expression may be closely related to the occurrence and development of uterine fibroids.
引文
[1]Donnez J,Dolmans M M.Uterine fibroid management:from the present to the future[J].Hum Reprod Update,2016,22(6):665-686.
[2]Ikhena D E,Bulun S E.Literature Review on the Role of Uterine Fibroids in Endometrial Function[J].Reprod Sci,2018,25(5):635-643.
[3]Silberzweig J E,Powell D K,Matsumoto A H,et al.Management of Uterine Fibroids:A Focus on Uterine-sparing Interventional Techniques[J].Radiology,2016,280(3):675-692.
[4]Slattery M L,Herrick J S,Pellatt D F,et al.MicroRNA profiles in colorectal carcinomas,adenomas and normal colonic mucosa:variations in miRNA expression and disease progression[J].Carcinogenesis,2016,37(3):245-261.
[5]张鑫,惠越,张燕,等.MicroRNA-21与细胞损伤及凋亡的研究进展[J].重庆医学,2017,46(1):120-123.
[6]郭婧澜,叶婷.miRNA在泌尿系统肿瘤发病、诊断及治疗中的作用研究进展[J].山东医药,2016,56(35):108-111.
[7]谢幸,苟文丽.妇产科学[M].8版.北京:人民卫生出版社,2013.
[8]欧阳晨捷.子宫肌瘤的发病机制研究进展[J].中南医学科学杂志,2016,44(6):708-711.
[9]刘素芳,姜泽允,郑凤俊,等.子宫肌瘤剔除术对不孕女性妊娠的影响及影响术后妊娠的相关因素分析[J].重庆医学,2017,11(A01):8-11.
[10]Li Y,Ran R,Guan Y,et al.Aberrant Methylation of the E-Cadherin Gene Promoter Region in the Endometrium of Women With Uterine Fibroids[J].Reprod Sci,2016,23(8):1096-1102.
[11]Song L,Shen L,Mandiwa C,et al.Induced and Spontaneous Abortion and Risk of Uterine Fibroids[J].J Womens Health(Larchmt),2017,26(1):76-81.
[12]Hartmann K E,Velez Edwards D R,Savitz D A,et al.Prospective Cohort Study of Uterine Fibroids and Miscarriage Risk[J].Am J Epidemiol,2017,186(10):1140-1148.
[13]陈超,李冬华,王满元,等.子宫肌瘤细胞凋亡机制及药物靶点治疗研究要点探析[J].医学研究杂志,2017,46(3):8-10,17.
[14]彭可可,欧阳伶宣,邓朝谦,等.MicroRNA研究概述[J].动物医学进展,2016,37(4):110-114.
[15]Jayawardana K,Schramm S J,Tembe V,et al.Identification,Review,and Systematic Cross-Validation of microRNAPrognostic Signatures in Metastatic Melanoma[J].J Invest Dermatol,2016,136(1):245-254.
[16]王思念,吕进,张巧云,等.miRNA与肿瘤侵袭转移[J].现代肿瘤医学,2016,24(3):485-487.
[17]Ganju A,Khan S,Hafeez B B,et al.miRNA nanotherapeutics for cancer[J].Drug Discovery Today,2017,22(2):424-432.
[18]Zhang Y,Lin J,Huang W,et al.The effect of circulating miR-223 on surveillance of different cancers:a meta-analysis[J].Onco Targets Ther,2017,10(2):3193-3201.
[19]魏永宝,杨金瑞,尹焯,等.miR-223生物学功能及在肿瘤中作用[J/OL].创伤与急诊电子杂志,2016,4(3):166-184.
[20]Wang F F,Zhang X J,Yan Y R,et al.FBX8 is a metastasis suppressor downstream of miR-223 and targeting mTOR for degradation in colorectal carcinoma[J].Cancer Lett,2017,388(7):85-95.
[21]Pinatel E M,Orso F,Penna E,et al.miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions[J].PLoS One,2014,9(1):859-864.
[2]Ikhena D E,Bulun S E.Literature Review on the Role of Uterine Fibroids in Endometrial Function[J].Reprod Sci,2018,25(5):635-643.
[3]Silberzweig J E,Powell D K,Matsumoto A H,et al.Management of Uterine Fibroids:A Focus on Uterine-sparing Interventional Techniques[J].Radiology,2016,280(3):675-692.
[4]Slattery M L,Herrick J S,Pellatt D F,et al.MicroRNA profiles in colorectal carcinomas,adenomas and normal colonic mucosa:variations in miRNA expression and disease progression[J].Carcinogenesis,2016,37(3):245-261.
[5]张鑫,惠越,张燕,等.MicroRNA-21与细胞损伤及凋亡的研究进展[J].重庆医学,2017,46(1):120-123.
[6]郭婧澜,叶婷.miRNA在泌尿系统肿瘤发病、诊断及治疗中的作用研究进展[J].山东医药,2016,56(35):108-111.
[7]谢幸,苟文丽.妇产科学[M].8版.北京:人民卫生出版社,2013.
[8]欧阳晨捷.子宫肌瘤的发病机制研究进展[J].中南医学科学杂志,2016,44(6):708-711.
[9]刘素芳,姜泽允,郑凤俊,等.子宫肌瘤剔除术对不孕女性妊娠的影响及影响术后妊娠的相关因素分析[J].重庆医学,2017,11(A01):8-11.
[10]Li Y,Ran R,Guan Y,et al.Aberrant Methylation of the E-Cadherin Gene Promoter Region in the Endometrium of Women With Uterine Fibroids[J].Reprod Sci,2016,23(8):1096-1102.
[11]Song L,Shen L,Mandiwa C,et al.Induced and Spontaneous Abortion and Risk of Uterine Fibroids[J].J Womens Health(Larchmt),2017,26(1):76-81.
[12]Hartmann K E,Velez Edwards D R,Savitz D A,et al.Prospective Cohort Study of Uterine Fibroids and Miscarriage Risk[J].Am J Epidemiol,2017,186(10):1140-1148.
[13]陈超,李冬华,王满元,等.子宫肌瘤细胞凋亡机制及药物靶点治疗研究要点探析[J].医学研究杂志,2017,46(3):8-10,17.
[14]彭可可,欧阳伶宣,邓朝谦,等.MicroRNA研究概述[J].动物医学进展,2016,37(4):110-114.
[15]Jayawardana K,Schramm S J,Tembe V,et al.Identification,Review,and Systematic Cross-Validation of microRNAPrognostic Signatures in Metastatic Melanoma[J].J Invest Dermatol,2016,136(1):245-254.
[16]王思念,吕进,张巧云,等.miRNA与肿瘤侵袭转移[J].现代肿瘤医学,2016,24(3):485-487.
[17]Ganju A,Khan S,Hafeez B B,et al.miRNA nanotherapeutics for cancer[J].Drug Discovery Today,2017,22(2):424-432.
[18]Zhang Y,Lin J,Huang W,et al.The effect of circulating miR-223 on surveillance of different cancers:a meta-analysis[J].Onco Targets Ther,2017,10(2):3193-3201.
[19]魏永宝,杨金瑞,尹焯,等.miR-223生物学功能及在肿瘤中作用[J/OL].创伤与急诊电子杂志,2016,4(3):166-184.
[20]Wang F F,Zhang X J,Yan Y R,et al.FBX8 is a metastasis suppressor downstream of miR-223 and targeting mTOR for degradation in colorectal carcinoma[J].Cancer Lett,2017,388(7):85-95.
[21]Pinatel E M,Orso F,Penna E,et al.miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions[J].PLoS One,2014,9(1):859-864.